A Phase I/II Study to Assess the Safety and Tolerability of APO866 for the Treatment of Refractory B-CLL

NCT00435084 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

B-cell Chronic Lymphocytic Leukemia

Interventions

DRUG: APO866

Sponsor

Valerio Therapeutics